Patritumab deruxtecan trials for Breast cancer

All Patritumab deruxtecan trials · All Breast cancer trials

Phase breakdown

Recruiting trials studying Patritumab deruxtecan for Breast cancer

• A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
  NCT07060807 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 199 locations
• Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd
  NCT06298084 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
  NCT06797635 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
• Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
  NCT06686394 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations

Common questions

How many trials study Patritumab deruxtecan for Breast cancer?

4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.